Biotech · Private company
Hookipa Biotech GmbH
Track this companyFree. Adds Hookipa Biotech GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- HB-101 vaccinePhase 2 · Cytomegalovirus (CMV) InfectionClinicalTrials.gov · fetched Nov 12, 2026
- HB-201 intravenous administration.Phase 2 · HPV-Related Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)Phase 2 · HPV-Related Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- HB-202 / HB-201 alternating intravenous administration + pembrolizumab.Phase 2 · HPV-Related Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- HB-202 intravenous administration alternating with HB-201 intravenous administration.Phase 2 · HPV-Related Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- HB-302/HB-301 Alternating 2-Vector TherapyPhase 2 · Prostate Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1Phase 1 · Human Immunodeficiency Virus (HIV) InfectionClinicalTrials.gov · fetched Nov 12, 2026
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 2Phase 1 · Human Immunodeficiency Virus (HIV) InfectionClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabOropharyngeal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabOropharyngeal Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ARTPHASE1 · TERMINATED · started Jul 1, 2024ClinicalTrials.gov NCT06430905 · fetched Nov 12, 2026
- Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaCOMPLETED · started Jun 5, 2024ClinicalTrials.gov NCT06771674 · fetched Nov 12, 2026
- A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · started Apr 15, 2024ClinicalTrials.gov NCT06373380 · fetched Nov 12, 2026
- HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate CancerPHASE1_PHASE2 · TERMINATED · started May 23, 2023ClinicalTrials.gov NCT05553639 · fetched Nov 12, 2026
- A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical CancerEARLY_PHASE1 · TERMINATED · started Jul 21, 2021ClinicalTrials.gov NCT04630353 · fetched Nov 12, 2026
- A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other CancersPHASE1_PHASE2 · COMPLETED · started Dec 11, 2019ClinicalTrials.gov NCT04180215 · fetched Nov 12, 2026
- A Study of CMV Vaccine (HB-101) in Kidney Transplant PatientsPHASE2 · COMPLETED · started Dec 12, 2018ClinicalTrials.gov NCT03629080 · fetched Nov 12, 2026